We are live on ! Find out more

SCYNEXIS

SCYX

Market cap $48.2M

4.60 USD

-0.24

4.96%

At close Updated Sep 14, 4:00 PM EDT

1 day

-4.96%

5 days

-13.21%

1 month

-11.2%

3 months

12.47%

6 months

-36.02%

Year to date

-9.98%

1 year

-47.73%

5 years

-90.37%

10 years

-98%

About: SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Employees: 29

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

SCYNEXIS to Participate in Upcoming Investor Conferences

JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:

SCYNEXIS to Participate in Upcoming Investor Conferences

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of the Senior Director's employment with the Company, as a material inducement to the employee's acceptance of employment, and was approved in accordance with Nasdaq Listing Rule 5635(c)(4).

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator.

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today reported financial results for the first quarter ended March 31, 2026.

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company's Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee's acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and certain rare diseases, today announced that it has entered into a definitive agreement with SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company A U.S. pharmaceutical company specializing in the deve.

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

SCYNEXIS Announces $40.0 Million Private Placement

JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors. The Company anticipates upfront gross proceeds from the private placement to be approximately $40.0 million, before deducting placement agent fees and transaction-related expenses, and up to an additional $52.2 million in gross proceeds if the Common Warrants are fully exercised for cash, subject to Stockholder Approval of shares of common stock issuable upon exercise of the Common Warrants. The private placement is expected to close on or about April 1, 2026, subject to the satisfaction of customary closing conditions.

SCYNEXIS Announces $40.0 Million Private Placement

See News Rankings

Price charts implemented using Lightweight Charts™